Always Remember - Buy The Dip

Sentiment Analysis For THRX

The news is currently generally neutral for THRX.

Based on TextBlob analysis of Yahoo! Finance news summaries for THRX on 2015-04-26.

Yahoo! Finance News for THRX

THRX Crosses Above Key Moving Average Level
In trading on Wednesday, shares of Theravance Inc (Symbol THRX) crossed above their 200 day moving average of $17.82, changing hands as high as $18.16 per share. Theravance Inc shares are currently trading up about 1.9% on the day.

7 High-Dividend Stocks in Healthcare
Source Flickr user Kat R. Dividend stocks tend to be the cornerstone of any well rounded retirement portfolio. Dividends are a beacon for investors to hone in on that demonstrate the

Pharmacyclics Begins Imbruvica Combination Cancer Study - Analyst Blog
Pharmacyclics, Inc.PCYC announced the initiation of a phase Ib II study to evaluate the safety, tolerability and effectiveness of Imbruvica in combination with AstraZeneca's AZN MEDI4736 in patients suffering from relapsed or refractory non small cell lung cancer, breast

Interesting THRX Put And Call Options For May 15th
Investors in Theravance Inc (Symbol THRX) saw new options become available this week, for the May 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the THRX options chain for the new May

Theravance/Glaxo's Breo Ellipta Gets Mixed FDA Panel View - Analyst Blog
Theravance, Inc.THRX and GlaxoSmithKline GSK announced mixed outcome from the joint meeting of the Pulmonary Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA regarding respiratory drug, Breo Ellipta (fluticasone furoate and a

Friday's ETF Movers: GDXJ, PBE
In trading on Friday, the Junior Gold Miners ETF ( GDXJ ) is outperforming other ETFs, up about 3.5% on the day. Components of that ETF showing particular strength include shares of Gold Resource Corporation ( GORO ), up

Wall Street On Track For Rebound In Quadruple Witching Session
Wall Street On Track For Rebound In Quadruple Witching Session

European Stocks Seen Flat-to-higher
European Stocks Seen Flat-to-higher

FOLD Expands, CERU Hits A High, FDA Panel Verdict Out On Breo Ellipta
FOLD Expands, CERU Hits A High, FDA Panel Verdict Out On Breo Ellipta

FDA Panel Recommends Approval Of GSK Asthma Drug For Adults But Not Adolescents
FDA Panel Recommends Approval Of GSK Asthma Drug For Adults But Not Adolescents

Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog
Pharmacyclics, Inc.PCYC announced that an Independent Data Monitoring Committee after reviewing the phase III HELIOS study has unanimously recommended that the study be unblinded based on clinically meaningful and statistically significant treatment benefit in patients receiving Imbruvica. The international,

Theravance Biopharma Q4 Loss Widens Y/Y, Revenues Up - Analyst Blog
Theravance Biopharma, Inc.TBPH reported fourth quarter 2014 loss of $2.02 per share, wider than a loss of $1.39 per share incurred a year ago. The Zacks Consensus Estimate was at a loss of $1.70. Theravance Biopharma was formed following

Heat Biologics' Bladder Cancer Drug Gets Fast Track Status - Analyst Blog
Heat Biologics, Inc.HTBX announced that it has received fast track designation from the FDA for its oncology candidate, HS 410 (vesigenurtacel L), for the treatment of non muscle invasive bladder cancer (NMIBC). Fast track status is granted to candidates

Theravance (THRX) Shares March Higher, Can It Continue? - Tale of the Tape
Theravance Inc ( THRX ) has been on the move lately as the stock has risen by 63.1% in the past four weeks, and it is currently trading well above its 20 Day SMA. This is a pretty solid

Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog
Isis Pharmaceuticals, Inc.ISIS announced that it has earned a milestone payment of $9 million from its partner Biogen BIIB . The milestone payment was related to the advancement of the ongoing pivotal phase III study (ENDEAR) on ISIS SMNRx

AVEO Up on Pipeline News, Q4 Loss Narrower than Expected - Analyst Blog
AVEO Pharmaceuticals, Inc.AVEO reported a fourth quarter 2014 loss of 24 cents per share, much narrower than the year ago loss of 32 cents and the Zacks Consensus Estimate of a loss of 28 cents. AVEO's shares were up

Forget Gilead Sciences (GILD), Buy These Biotech Stocks Instead - Stocks in the News
Gilead, without a doubt, has proven itself to be a leader in the biotechnology industry. The stock has had an extremely bullish pattern over the last four years, growing over 400% in stock price since March 2011. However, over

Pharmacyclics Set to Be Acquired by AbbVie for $21B - Analyst Blog
Pharmacyclics Inc. 's PCYC shares were up 10.3% after a definitive agreement was announced under which AbbVie Inc. ABBV will acquire Pharmacyclics. AbbVie will pay $261.25 per share, consisting of cash (58%) and equity (42%). The deal is valued

Shire Submits NDA for Dry Eye Disease Drug Lifitegrast - Analyst Blog
Pipeline and regulatory updates are highly awaited events in the pharma biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at

BMY, VRX Open Wallet, LLY Does It Again, RIGL Gets A Regal Touch, TRIB Is Back
BMY, VRX Open Wallet, LLY Does It Again, RIGL Gets A Regal Touch, TRIB Is Back

BMY, VRX Open Wallet, LLY Does It Again, RIGL Gets A Regal Touch, TRIB Is Back
BMY, VRX Open Wallet, LLY Does It Again, RIGL Gets A Regal Touch, TRIB Is Back

GSK,Theravance Start Phase III Lung Function Study For COPD - Quick Facts
GSK,Theravance Start Phase III Lung Function Study For COPD - Quick Facts

Glaxo, Theravance Begin Second Global Phase III Lung Function Study
Glaxo, Theravance Begin Second Global Phase III Lung Function Study